Comparing the current results to its competitors, Tff Pharmaceuticals Inc reported Revenue decrease in the 3 quarter 2024 year on year by -17.62 %, despite the revenue increase by the most of its competitors of 66.8 %, recorded in the same quarter.
September 26, 2024
The quest for improved delivery methods for pharmaceutical treatments has led researchers to explore diverse routes, with inhalational therapy gaining momentum due to its potential for localized and efficient drug administration. TFF Pharmaceuticals is at the forefront of this innovative field, as highlighted by two significant developments in their research the exploration of their advanced thin film freezing (TFF) technology for inhalational dry powder formulations and the ongoing clinical trials for their Tacrolimus Inhalation Powder (TFF TAC) aimed at preventing lung transplant rejection. Cutting-Edge Technology: Thin Film Freezing for Inhalational FormulationsRecent research published in the Journal ...
September 11, 2024
In an unprecedented cooperative effort aimed at innovating treatments for respiratory illnesses, TFF Pharmaceuticals has formed a strategic partnership with Emory University and the Biomedical Advanced Research and Development Authority (BARDA). This collaboration is centered around the development of a dry powder inhaled formulation of messenger RNA (mRNA) aimed at addressing both influenza and COVID-19, conditions that have posed significant public health challenges worldwide. The Collaboration and Its sTFF Pharmaceuticals, known for its revolutionary thin-film freezing (TFF) technology, is at the forefront of this initiative. The crux of the partnership lies in leveraging its proprietary technology to cre...
June 24, 2024
Accelerating Innovations: Regulatory and Preclinical Advances in TFF Pharmaceuticals Pipeline Regulatory Update on Tacrolimus Inhalation Powder (TFF TAC) Clinical ProgramIn a significant stride towards pioneering advancements in therapies for lung transplant rejection, TFF Pharmaceuticals, Inc. (Nasdaq: TFFP), a clinical-stage biopharmaceutical entity, recently provided an essential regulatory update concerning its Tacrolimus Inhalation Powder (TFF TAC) clinical program. The FDA has provided constructive feedback intended to steer the next steps in the development of TFF TAC, fostering an accelerated path forward for this promising therapeutic candidate.Tacrolimus Inhalation Powder is specifically engineer...
May 23, 2024
The field of biodefense has significantly evolved in recent years with the emergence of novel threats, necessitating the development of more efficient and rapid countermeasures. In line with this , TFF Pharmaceuticals and Leidos have joined forces under the DARPA PPB program to advance next-generation medical countermeasures (MCMs) using TFF Pharmaceuticals proprietary Thin Film Freezing Technology. This article provides an overview of how this collaboration will facilitate the preclinical testing and formulation of innovative biodefense countermeasures.Thin Film Freezing Technology: A Revolutionary ApproachThin Film Freezing (TFF) is a cutting-edge technology developed by TFF Pharmaceuticals that enables t...
April 29, 2024
In the continually advancing field of biopharmaceuticals, TFF Pharmaceuticals has shone as a beacon of innovation. The biopharmaceutical company s latest contribution to the field of medical research, specifically, in the domain of organ transplantation medicines, manifests in the form of their Phase 2 data on Tacrolimus Inhalation Powder or TFF TAC, for the prevention of lung transplant rejection. This unparalleled medical breakthrough was presented recently at the Annual Meeting of the International Society for Heart and Lung Transplantation (ISHLT).TFF Pharmaceuticals is known for its inventive approach to medical science, transforming the existing landscape of health and medicine through the promotion of...
March 27, 2024
TFF Pharmaceuticals, a cutting-edge pharmaceutical company focused on developing innovative inhalable drug therapies, recently updated their clinical programs for Tacrolimus Inhalation Powder (TFF TAC) and Voriconazole Inhalation Powder (TFF VORI). These programs have showcased promising results in improving patient outcomes with reduced systemic exposures. In particular, the successful transition of eight lung transplant patients from oral Tacrolimus to TFF TAC, without encountering acute rejection, provides significant insights into the potential of this novel formulation.TFF Pharmaceuticals has announced encouraging results from its ongoing clinical programs involving Tacrolimus and Voriconazole inhalatio...
Vapotherm Inc operates under a business model that focuses on providing innovative respiratory support solutions to hospitals and healthcare facilities. They offer high-flow therapy systems and devices that deliver heated, humidified, and oxygenated air to patients with respiratory issues, aiming to improve patient outcomes and reduce the need for invasive interventions. Through strategic partnerships with hospitals and direct sales to healthcare providers, Vapotherm aims to both improve patient care and generate revenue from the sales of their products.
Capricor Therapeutics Inc's business model revolves around developing innovative regenerative medicine therapies for the treatment of diseases that have unmet medical needs.
Ardelyx Inc is a biopharmaceutical company that focuses on the development of novel, minimally-absorbed small molecules to treat gastrointestinal diseases. Their business model revolves around identifying specific needs within the gastrointestinal field and leveraging their research and development capabilities to create innovative therapeutic solutions. By partnering with other pharmaceutical companies and pursuing strategic collaborations, Ardelyx aims to bring its products to market and ultimately improve patient outcomes in the gastrointestinal space.
Sources:
Tff Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Tff Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
